Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time they enter the study
- People whose medical records, including prescriptions, diagnoses, and medical history, are available for at least 12 months before their entry into the study
- People who have been diagnosed with type 2 diabetes at or before their entry into the study
- People (in the exenatide group) who have been newly prescribed the diabetes medication exenatide (sold as BYETTA or BYDUREON/BYDUREON BCise) during the study period, and who were previously on a different type of diabetes medication
- People (in the comparison group) who have been newly prescribed a diabetes medication other than certain specific drug types (DPP-4 inhibitors or GLP-1 receptor agonists), and who were previously on a different type of diabetes medication
Who may not be able to join:
- People who have a diagnosis of type 1 diabetes at or before their entry into the study (unless a type 2 diabetes diagnosis followed it during the lead-up period)
- People who have been diagnosed with gestational diabetes (diabetes during pregnancy) during the lead-up period or at the time of entry into the study
- People diagnosed with polycystic ovarian syndrome who were only ever prescribed metformin as their diabetes medication during the lead-up period or at entry into the study
- People with a history of any cancer at or before their entry into the study (except for a common type of non-melanoma skin cancer, which does not disqualify someone)
- People with a history of acute pancreatitis, or any other pancreas-related disease or disorder, at or before their entry into the study
- People who have previously been prescribed a GLP-1 receptor agonist diabetes medication other than exenatide at or before their entry into the study (confirm with trial site if unsure which medications fall into this category)
- People who have previously been prescribed a DPP-4 inhibitor diabetes medication at or before their entry into the study (confirm with trial site if unsure which medications fall into this category)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fabian Hoti, PhD, IQVIA Pty Ltd
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population; Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.